Anti-CD20 monoclonal antibodies: reviewing a revolution

References

• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. In: B cell trophic factors and B cell antagonism in autoimmune disease. Basel: KARGER. 2004. p. 140–174.
   Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15:S3. doi:10.1186/ar3908.
   PubMed Web of Science ®Google Scholar
• Oldham RJ, Cleary KLS, Cragg MS. CD20 and its antibodies: past, present, and future. For Immunopathol Dis Therap. 2014;5:7–23. doi:10.1615/ForumImmunDisTher.2015014073.
   Google Scholar
• Bubien JK. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121:1121–1132. doi:10.1083/jcb.121.5.1121.
   PubMed Web of Science ®Google Scholar
• Walshe CA, Beers SA, French RR, Chan CHT, Johnson PW, Packham GK, Glennie MJ, Cragg MS. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283:16971–16984. doi:10.1074/jbc.M708459200.
   PubMed Web of Science ®Google Scholar
• Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. J Biol Chem. 2008;283:18545–18552. doi:10.1074/jbc.M800784200.
   PubMed Web of Science ®Google Scholar
• Morsy DED, Sanyal R, Zaiss AK, Deo R, Muruve DA, Deans JP. Reduced T-dependent humoral immunity in CD20-deficient mice. J Immunol. 2013;191:3112–3118. doi:10.4049/jimmunol.1202098.
   PubMed Web of Science ®Google Scholar
• Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IAM, Dolman KM, Beaumont T, Tedder TF, van Noesel CJM, Eldering E, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120:214–222. doi:10.1172/JCI40231.
   PubMed Web of Science ®Google Scholar
• Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67:134–140. doi:10.1172/JCI110005.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8;2005:140–174.
   PubMedGoogle Scholar
• Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017;8:1327–1422. doi:10.3389/fimmu.2017.01245.
   PubMed Web of Science ®Google Scholar
• Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7;1988:711–717.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, de Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 51;1998:364–369.
   PubMed Web of Science ®Google Scholar
• Cleary KLS, Chan HTC, James S, Glennie MJ, Cragg MS. Antibody distance from the cell membrane regulates antibody effector mechanisms. J Immunol. 2017;198:3999–4011. doi:10.4049/jimmunol.1601473.
   PubMed Web of Science ®Google Scholar
• Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem. 1998;273:344–348. doi:10.1074/jbc.273.1.344.
   PubMed Web of Science ®Google Scholar
• Pike LJ. Rafts defined: a report on the Keystone symposium on lipid rafts and cell function. J Lipid Res. 2006;47:1597–1598. doi:10.1194/jlr.M600040-JLR200.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HTC, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191–5201. doi:10.1182/blood-2009-12-255992.
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke A, Wiechmann K, Jenewein S, Slootstra JW, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118:358–367. doi:10.1182/blood-2011-02-334870.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, French RR, Glennie MJ. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:1045–1052. doi:10.1182/blood-2002-06-1761.
   PubMed Web of Science ®Google Scholar
• Golan MD, Burger R, Loos M. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol. 129;1982:445–447.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJM, Wiegman LJJM, van den Brakel JHN, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362–371. doi:10.4049/jimmunol.177.1.362.
   PubMed Web of Science ®Google Scholar
• de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 2016;14:e1002344. doi:10.1371/journal.pbio.1002344.
   PubMed Web of Science ®Google Scholar
• Pross HF, Maroun JA. The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods. 1984;68:235–249. doi:10.1016/0022-1759(84)90154-6.
   PubMed Web of Science ®Google Scholar
• Gül N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 2015;75:5008–5013. doi:10.1158/0008-5472.CAN-14-3569.
   PubMed Web of Science ®Google Scholar
• Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 97;2001:1392–1398.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–3837. doi:10.1016/j.molimm.2007.06.151.
   PubMed Web of Science ®Google Scholar
• Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139:439–446. doi:10.1111/j.1365-2249.2005.02720.x.
   PubMed Web of Science ®Google Scholar
• Bellosillo B, Villamor N, Lopez-Guillermo A, Marcé S, Esteve J, Campo E, Colomer D, Montserrat E. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 98;2001:2771–2777.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–446. doi:10.1038/74704.
   PubMed Web of Science ®Google Scholar
• de Haij S, Jansen JHM, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PWHI, van de Winkel JGJ, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010;70:3209–3217. doi:10.1158/0008-5472.CAN-09-4109.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–758. doi:10.1182/blood.V99.3.754.
   PubMed Web of Science ®Google Scholar
• Abès R, Gélizé E, Fridman WH, Teillaud J-L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116:926–934. doi:10.1182/blood-2009-10-248609.
   PubMed Web of Science ®Google Scholar
• Ghesquières H, Cartron G, Seymour JF, Delfau-Larue M-H, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood. 2012;120:2650–2657. doi:10.1182/blood-2012-05-431825.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ, Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood. 2009;113:3809–3812. doi:10.1182/blood-2008-03-146472.
   PubMed Web of Science ®Google Scholar
• Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y, Peng H, Fu Y-X. CTLA-4 limits anti-CD20-mediated tumor regression. Clin Cancer Res. 2017;23:193–203. doi:10.1158/1078-0432.CCR-16-0040.
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CHT, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47:107–114. doi:10.1053/j.seminhematol.2010.01.001.
   PubMed Web of Science ®Google Scholar
• Kellner C, Otte A, Cappuzzello E, Klausz K, Peipp M. Modulating cytotoxic effector functions by Fc engineering to improve cancer therapy. Transfus Med Hemother. 2017;44:327–336. doi:10.1159/000479980.
   PubMed Web of Science ®Google Scholar
• Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004;25:158–164. doi:10.1016/j.it.2004.01.008.
   PubMed Web of Science ®Google Scholar
• Wang S-Y, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111:1456–1463. doi:10.1182/blood-2007-02-074716.
   PubMed Web of Science ®Google Scholar
• Wang S-Y, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel C-W, St John W, Weiner GJ. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009;114:5322–5330. doi:10.1182/blood-2009-04-215525.
   PubMed Web of Science ®Google Scholar
• Racila E, Link BK, Weng W-K, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008;14:6697–6703. doi:10.1158/1078-0432.CCR-08-0745.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–26740. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Smolewski P, Robak T. The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma. Expert Opin Drug Discov. 2015;10:doi:10.1517/17460441.2015.1045295.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83;1994:435–445.
   PubMed Web of Science ®Google Scholar
• Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40;1980:3147–3154.
   PubMed Web of Science ®Google Scholar
• Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517–522. doi:10.1056/NEJM198203043060906.
   PubMed Web of Science ®Google Scholar
• Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 69;1987:584–591.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003;9:269–277. doi:10.1038/nm0303-269.
   PubMed Web of Science ®Google Scholar
• Liu AY, Robinson RR, Murray ED, Ledbetter JA, Hellström I, Hellström KE. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol. 139;1987:3521–3526.
   PubMed Web of Science ®Google Scholar
• Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs. 2013;5:826–837. doi:10.4161/mabs.22965.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833. doi:10.1200/JCO.1998.16.8.2825.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995–1001. doi:10.1023/A:1008416911099.
   PubMed Web of Science ®Google Scholar
• Rozman S, Grabnar I, Novaković S, Mrhar A, Jezeršek Novaković B. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol. 2017;83:1782–1790. doi:10.1111/bcp.v83.8.
   PubMed Web of Science ®Google Scholar
• Yin A, Li J, Hurst D, Visich J. Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28:e13108–e131088. doi:10.1200/jco.2010.28.15_suppl.e13108.
   Web of Science ®Google Scholar
• Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, Mangat R, Joshi A, Visich J. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52:1918–1926. doi:10.1177/0091270011430506.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MHJ, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276–3284. doi:10.1182/blood-2011-10-388512.
   PubMed Web of Science ®Google Scholar
• Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97:1431–1438. doi:10.3324/haematol.2011.059246.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462–4469. doi:10.1200/JCO.2012.41.9416.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Held G, Zeynalova S, Zwick C, Haenel M, Truemper L, Dreyling MH, Dierlamm J, Loeffler M, Schmitz N, et al. Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: results from the SEXIE-R-CHOP-14 trial of the DSHNHL. J Clin Oncol. 2014;32:8501–8511. doi:10.1200/JCO.2013.54.6911.
   Web of Science ®Google Scholar
• Davies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P, Rule S, Rummel M, McIntyre C, Smith R, Badoux X. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34:2210–2231. doi:10.1007/s12325-017-0610-z.
   PubMed Web of Science ®Google Scholar
• Mao C-P, Brovarney MR, Dabbagh K, Birnböck HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS ONE. 2013;8:e80533. doi:10.1371/journal.pone.0080533.
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter WF, Hourcade-Potelleret F, Herting F, Schmidt J. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg). 2014;64:569–575. doi:10.1055/s-00023610.
   PubMedGoogle Scholar
• Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32:1782–1791. doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljević B, Siritanaratkul N, Solal-Céligny P, Barrett M, Berge C, Bittner B, Boehnke A, McIntyre C, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15:343–352. doi:10.1016/S1470-2045(13)70510-2.
   PubMed Web of Science ®Google Scholar
• Assouline S, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, Brewster M, Catalani O, Li S, McIntyre C, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3:e128–38. doi:10.1016/S2352-3026(16)00004-1.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Celigny P, Boehnke A, Berge C, Genevray M, Zharkov A, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4:e272–82. doi:10.1016/S2352-3026(17)30078-9.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau J-P, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102:1913–1922. doi:10.3324/haematol.2016.158808.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, Re F, Trask P, Osborne S, Smith R, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28:836–842. doi:10.1093/annonc/mdx075.
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, Trümper L, Brugger W, Ostermann H, Atzpodien J, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79:493–500. doi:10.1007/s002770000163.
   PubMed Web of Science ®Google Scholar
• Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol. 2000;109:81–88. doi:10.1046/j.1365-2141.2000.01965.x.
   PubMed Web of Science ®Google Scholar
• Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, et al. Single-agent monoclonal antibody efficacy in bulky Non-Hodgkin’s Lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999;17:1851–1861. doi:10.1200/JCO.1999.17.6.1851.
   PubMed Web of Science ®Google Scholar
• Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1999;10:655–661. doi:10.1023/A:1008389119525.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579–4586. doi:10.1200/JCO.2007.15.2777.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732. doi:10.1182/blood-2004-04-1622.
   PubMed Web of Science ®Google Scholar
• Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica. 2013;98:1107–1114. doi:10.3324/haematol.2012.082412.
   PubMed Web of Science ®Google Scholar
• van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van’t Veer M, Vranovsky A, Holte H, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–3301. doi:10.1182/blood-2006-03-013334.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51. doi:10.1016/S0140-6736(10)62175-7.
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Bouabdallah R, Catalano J, Brice P, et al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Blood. 2017;130:486–496.
   Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32:3096–3102. doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• van Oers MHJ, van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853–2858. doi:10.1200/JCO.2009.26.5827.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MHJ, Fortpied C, Ghielmini M, Pettengell R, et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Eur J Cancer. 2017;76:216–225. doi:10.1016/j.ejca.2017.01.021.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–4088. doi:10.1200/JCO.2005.12.051.
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf W-U, Aulitzky W-E, Hensel M, Herold M, Huhn D, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115–3120. doi:10.1182/blood-2002-03-0706.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165–2170. doi:10.1200/JCO.2001.19.10.2674.
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do K-A, Cortes J, Koller C, Beran M, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–4078. doi:10.1200/JCO.2005.12.516.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174. doi:10.1016/S0140-6736(10)61381-5.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, Tresckow von J, Engelke A, Maurer C, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–215. doi:10.1182/blood-2015-06-651125.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–309. doi:10.1182/blood-2015-09-667675.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–942. doi:10.1016/S1470-2045(16)30051-1.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy M-S, Illmer T, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110. doi:10.1056/NEJMoa1313984.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LFC, Montillo M, Fegan C, Asikanius E, Humphrey K, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 2013 28:3;29:1602–1604. doi:10.1038/leu.2014.245.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–1765. doi:10.1200/JCO.2009.26.4556.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–3566. doi:10.1200/JCO.2010.33.8061.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32:1236–1241. doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes Da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25. doi:10.1093/annonc/mdv383.
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:389–397. doi:10.1200/JCO.2001.19.10.2674.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. doi:10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127. doi:10.1200/JCO.2005.05.1003.
   PubMed Web of Science ®Google Scholar
• Feugier P, van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d“Etude des Lymphomes de l”Adulte. J Clin Oncol. 2005;23:4117–4126. doi:10.1200/JCO.2005.09.131.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, van den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d“Etudes des Lymphomes de l”Adulte. Blood. 2010;116:2040–2045. doi:10.1182/blood-2010-03-276246.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P-L, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391. doi:10.1016/S1470-2045(06)70664-7.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–1022. doi:10.1016/S1470-2045(11)70150-4.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WLJ, Van ‘t Veer MB, Zijlstra JM, Fibbe WE, van Oers MHJ, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111:537–543. doi:10.1182/blood-2007-08-108415.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(Suppl 1):i5–10. doi:10.1093/annonc/mdg702.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O’Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688. doi:10.1182/blood-2003-11-3911.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, de Chiara A, Morelli E, Capobianco G, Becchimanzi C, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and “unclassifiable” highly aggressive B-cell lymphoma. Br J Haematol. 2012;156:234–244. doi:10.1111/j.1365-2141.2011.08947.x.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165:102–111. doi:10.1111/bjh.12736.
   PubMed Web of Science ®Google Scholar
• Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, et al. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol. 2013;24:3076–3081. doi:10.1093/annonc/mdt414.
   PubMed Web of Science ®Google Scholar
• Ribera J-M, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas J-M, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119:1660–1668. doi:10.1002/cncr.27918.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker L-M, Recher C, Ghesquières H, Morschhauser F, Girault S, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402–2411. doi:10.1016/S0140-6736(15)01317-3.
   PubMed Web of Science ®Google Scholar
• Raponi S, de Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, Perbellini O, Pizzolo G, Foà R, Guarini A. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098–1107. doi:10.3109/10428194.2010.535182.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113:6330–6337. doi:10.1182/blood-2008-03-146472.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880–3889. doi:10.1200/JCO.2009.26.9456.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Huettmann A, Kaul F, Irmer S, Jaekel N, Mohren M, Lipp T, Wedelin K, de Valle F, Schmid M, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood. 2010;116:170.
   Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044–1053. doi:10.1056/NEJMoa1605085.
   PubMed Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, van Puijenbroek E, Lang S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–2042. doi:10.1158/1535-7163.MCT-12-1016-T.
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402. doi:10.1182/blood-2009-12-255992.
   PubMed Web of Science ®Google Scholar
• Patz M, Isaeva P, Forcob N, Müller B, Frenzel LP, Wendtner C-M, Klein C, Umana P, Hallek M, Krause G. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2010;152:295–306. doi:10.1111/j.1365-2141.2010.08444.x.
   PubMed Web of Science ®Google Scholar
• Herting F, Friess T, Bader S, Muth G, Hölzlwimmer G, Rieder N, Umana P, Klein C. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014;55:2151–5160. doi:10.3109/10428194.2013.856008.
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119:5126–5132. doi:10.1182/blood-2011-10-388512.
   PubMed Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Solal-Celigny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920–2926. doi:10.1200/JCO.2013.49.0219.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20 +Indolent B-cell non-hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33:3467–3474. doi:10.1200/JCO.2014.59.2139.
   PubMed Web of Science ®Google Scholar
• Cartron G, Hourcade-Potelleret F, Morschhauser F, Salles G, Wenger M, Truppel-Hartmann A, Carlile DJ. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica. 2016;101:226–234. doi:10.3324/haematol.2016.143271.
   PubMed Web of Science ®Google Scholar
• Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma and Exposure–response in CLL. CPT. 3;2014:e144–11.
   Google Scholar
• Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, Wenger M, Lei G, Wassner-Fritsch E, Vitolo U. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122:1137–1143. doi:10.1182/blood-2012-12-471029.
   PubMed Web of Science ®Google Scholar
• Grigg A, Dyer MJS, Díaz MG, Dreyling M, Rule S, Lei G, Knapp A, Wassner-Fritsch E, Marlton P. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. 2017;102:765–772. doi:10.3324/haematol.2016.158808.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–1093. doi:10.1016/S1470-2045(16)30097-3.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;JCO.2017.76:365–410.
   Google Scholar
• Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–1344. doi:10.1056/NEJMoa1614598.
   PubMed Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy M-S, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124:2196–2202. doi:10.1182/blood-2014-07-586610.
   PubMed Web of Science ®Google Scholar
• Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015;125:2779–2785. doi:10.1182/blood-2014-07-591040.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy M-S, Wickham N, de Guibert S, Ritgen M, Langerak AW, Bieska G, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia. 2013 2013 28:3;27:1172–1174. doi:10.1038/leu.2012.252.
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122:3482–3491. doi:10.1182/blood-2012-12-471029.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Dyer MJS, Muller L, Smolej L, Di Bernado MC, Knapp A, Nielsen T, Hallek M. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. Stockholm. 2018.
   Google Scholar
• Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126:2646–2649. doi:10.1182/blood-2015-09-670802.
   PubMed Web of Science ®Google Scholar
• Freeman CL, Dixon M, Houghton R, Kreuzer K-A, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, et al. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016 2013 28:3;30:1763–1766. doi:10.1038/leu.2016.124.
   PubMed Web of Science ®Google Scholar
• Bosch F, Illmer T, Turgut M, Cortelezzi A, Lasserre SF, Truppel-Hartmann A, Leblond V, Foà R, Stilgenbauer S. Preliminary safety results from the phase IIIb GREEN study of obinutuzumab (GA101) alone or in combination with chemotherapy for previously untreated or relapsed/refractory Chronic Lymphocytic Leukemia (CLL). Blood. 124;2014:3345.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, et al. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2013 28:3 2018;26:15.
   Google Scholar
• Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129:2702–2705. doi:10.1182/blood-2017-01-761973.
   PubMed Web of Science ®Google Scholar
• Cramer P, Tresckow von J, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner C-M, Kreuzer K-A, Stilgenbauer S, et al. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Fut Oncol. 2018;14:499–513. doi:10.2217/fon-2017-0442.
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912–2919. doi:10.1200/JCO.2013.49.0219.
   PubMed Web of Science ®Google Scholar
• Mobasher M, Costa LJ, Flinn I, Flowers CR, Kaminski MS, Sandmann T, Trunzer K, Vignal C, Forero-Torres A. Safety and efficacy of obinutuzumab (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 gather study (GAO4915g). Blood. 2013;122:1820. doi:10.1182/blood-2012-12-471029.
   Web of Science ®Google Scholar
• Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–3537. doi:10.1200/JCO.2017.73.3402.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PWHI, Hack CE, Dechant M, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–1800. doi:10.1182/blood-2003-11-3979.
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, Golay J. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013;190:231–239. doi:10.4049/jimmunol.1202645.
   PubMed Web of Science ®Google Scholar
• Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008;68:2400–2408. doi:10.1158/0008-5472.CAN-07-6663.
   PubMed Web of Science ®Google Scholar
• Craigen JL, Mackus WJM, Engleberts P, Miller SR, Speller S, Chamberlain LC, Davis BG, McHugh SM, Bullmore E, Cox CJ, et al. Ofatumumab, a human mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC. Blood. 2009;114:1725–1735. doi:10.1182/blood-2009-04-215525.
   PubMed Web of Science ®Google Scholar
• Cillessen SAGM, Mackus WJM, Castricum KCM, Vos W, Kortman PC, van de Winkel JGJ, Parren PWHI, Meijer CJLM, Oudejans JJ. Intr. by Ole Baadsgaard. Chemotherapy-refractory Diffuse Large B-Cell Lymphomas (DLBCL) are effectively killed by Ofatumumab-induced complement-mediated cytoxicity. Blood. 110;2007:2346–2356.
   Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486–5495. doi:10.1182/blood-2007-10-117671.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119:3698–3704. doi:10.1182/blood-2011-10-388512.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012;157:438–445. doi:10.1111/j.1365-2141.2012.09086.x.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, Banat GA, Grünhagen von U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210. doi:10.1016/S0140-6736(12)61763-2.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MHJ, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094–1100. doi:10.1182/blood-2007-09-111781.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–1755. doi:10.1200/JCO.2009.25.3187.
   PubMed Web of Science ®Google Scholar
• Laurenti L, Innocenti I, Autore F, Sica S, Efremov D. New developments in the management of chronic lymphocytic leukemia: role of ofatumumab. OTT. 2016:421–429. doi:10.2147/OTT.
   Google Scholar
• Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223. doi:10.1056/NEJMoa1410490.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, et al. Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial. Leukemia. 2014 2013 28:3;28:642–648. doi:10.1038/leu.2014.105.
   PubMed Web of Science ®Google Scholar
• Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017;58:1084–1093. doi:10.1080/10428194.2016.1233536.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Fanning SR, Stephenson J, Afrin LB, Kistner-Griffin E, Bentz TA, Stuart RK. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015;56:645–649. doi:10.3109/10428194.2014.905773.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126:842–850. doi:10.1182/blood-2014-12-617522.
   PubMed Web of Science ®Google Scholar
• Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4:e114–26. doi:10.1016/S2352-3026(17)30019-4.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Ruppert AS, Harwin W, Waterhouse D, Papish S, Jones JA, Hainsworth J, Byrd JC. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. Am J Hematol. 2016;91:1020–1025. doi:10.1002/ajh.v91.10.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117:6450–6458. doi:10.1182/blood-2010-12-323980.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, Doubek M, Panagiotidis P, Kimby E, Schuh A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873–1883. doi:10.1016/S0140-6736(15)60027-7.
   PubMed Web of Science ®Google Scholar
• van Oers MHJ, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin M-D, Gupta I, Phillips J, Williams V, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015;16:1370–1379. doi:10.1016/S1470-2045(15)00143-6.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, et al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol. 2013;163:334–342. doi:10.1111/bjh.12537.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013;122:499–506. doi:10.1182/blood-2012-12-471029.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190. doi:10.1200/JCO.2010.28.1618.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35:544–551. doi:10.1200/JCO.2016.69.0198.
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094–1108. doi:10.1016/S0140-6736(10)60826-4.
   PubMed Web of Science ®Google Scholar
• Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev. 2007;7:137–142. doi:10.1016/j.autrev.2007.02.017.
   PubMed Web of Science ®Google Scholar
• Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581. doi:10.1056/NEJMoa032534.
   PubMed Web of Science ®Google Scholar
• Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629–1635.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Tak PP, Zerbini C, Tremblay J-L, Carreño L, Armstrong G, Collinson N, Shaw TM. MIRROR trial investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683–1693. doi:10.1093/rheumatology/keq116.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester G-R, Cravets MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806. doi:10.1002/art.22025.
   PubMed Web of Science ®Google Scholar
• Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP. RESET investigators. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET trial. J Rheumatol. 2011;38:2548–2556. doi:10.3899/jrheum.100724.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, Cravets M, Shaw T, Hagerty D. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69:1158–1161. doi:10.1136/ard.2009.119222.
   PubMed Web of Science ®Google Scholar
• Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39–46. doi:10.1136/ard.2010.139832.
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PLCM, Nordström DC, Gomez-Reino J, Pavelka K, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374–377. doi:10.1136/annrheumdis-2011-200003.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1101–1136. doi:10.1136/annrheumdis-2016-210708.
   PubMed Web of Science ®Google Scholar
• Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477–484. doi:10.7326/0003-4819-124-5-199603010-00003.
   PubMed Web of Science ®Google Scholar
• Huong DLT, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette J-C. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 29;2002:2571–2576.
   PubMed Web of Science ®Google Scholar
• Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW, Differential B. T-cell activation in Wegener’s granulomatosis. J Allergy Clin Immunol. 1999;103:885–894. doi:10.1016/S0091-6749(99)70434-3.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232. doi:10.1056/NEJMoa1011205.
   PubMed Web of Science ®Google Scholar
• Stevenson HC, Fauci AS. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology. 39;1980:391–397.
   PubMed Web of Science ®Google Scholar
• Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol. 128;1982:2453–2457.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–1780. doi:10.1056/NEJMoa1410490.
   PubMed Web of Science ®Google Scholar
• Bengtsson AA, Rönnblom L. Systemic lupus erythematosus: still a challenge for physicians. J Intern Med. 2017;281:52–64. doi:10.1111/joim.12529.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215–1226. doi:10.1002/art.34359.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh H-J, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–233. doi:10.1002/art.27631.
   PubMed Web of Science ®Google Scholar
• Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018;27:802–811. doi:10.1177/0961203317749047.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA. RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:1653–1661. doi:10.1016/S0140-6736(14)61495-1.
   PubMed Web of Science ®Google Scholar
• Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol. 2014;167:243–251. doi:10.1111/bjh.2014.167.issue-2.
   PubMed Web of Science ®Google Scholar
• Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–696. doi:10.1016/j.autrev.2014.01.053.
   PubMed Web of Science ®Google Scholar
• Wang -H-H, Liu C-W, Li Y-C, Huang Y-C. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928–932. doi:10.2340/00015555-2116.
   PubMed Web of Science ®Google Scholar
• Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S, Brette M-D, Soued I, Gabison É, Aucouturier F, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147:843–849. doi:10.1001/archdermatol.2010.303.
   PubMed Web of Science ®Google Scholar
• Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262:1115–1119. doi:10.1007/s00415-015-7653-3.
   PubMed Web of Science ®Google Scholar
• Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler. 2016;22:955–959. doi:10.1177/1352458515602337.
   PubMed Web of Science ®Google Scholar
• Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017;56:26–36. doi:10.1093/rheumatology/kew146.
   PubMed Web of Science ®Google Scholar
• Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol. 2007;63:47–52. doi:10.1016/j.critrevonc.2006.11.004.
   PubMed Web of Science ®Google Scholar
• Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost. 2011;9:1429–1431. doi:10.1111/j.1538-7836.2011.04345.x.
   PubMed Web of Science ®Google Scholar
• Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163:393–399. doi:10.1111/bjh.12541.
   PubMed Web of Science ®Google Scholar
• Laribi K, Bolle D, Ghnaya H, Sandu A, Besançon A, Denizon N, Truong C, Pineau-Vincent F, de Materre AB. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Ann Hematol. 2016;95:765–769. doi:10.1007/s00277-016-2605-2.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Rajapakse S, Gooneratne L. Rituximab in the treatment of autoimmune haemolytic anaemia. Br J Clin Pharmacol. 2015;79:709–719. doi:10.1111/bcp.12498.
   PubMed Web of Science ®Google Scholar
• Westwood J-P, Thomas M, Alwan F, McDonald V, Benjamin S, Lester WA, Lowe GC, Dutt T, Hill QA, Scully M. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2017;1:1159–1166. doi:10.1182/bloodadvances.2017008268.
   PubMed Web of Science ®Google Scholar
• Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746–1753. doi:10.1182/blood-2011-02-334870.
   PubMed Web of Science ®Google Scholar
• Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016;127:3092–3094. doi:10.1182/blood-2016-03-703827.
   PubMed Web of Science ®Google Scholar
• Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmun Highlights. 2017;8:1–12. doi:10.1007/s13317-017-0100-y.
   PubMed Web of Science ®Google Scholar
• Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3–10. doi:10.1016/j.ymeth.2005.01.001.
   PubMed Web of Science ®Google Scholar
• van Brummelen EMJ, Ros W, Wolbink G, Beijnen JH, Schellens JHM. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist. 2016;21:1260–1268. doi:10.1634/theoncologist.2015-0336.
   PubMed Web of Science ®Google Scholar
• Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 90;2017:1352458517720044.
   Google Scholar
• Rioufol C, Salles G. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. Expert Rev Anticancer Ther. 2015;15:569–578. doi:10.1586/14737140.2015.1028919.
   PubMed Web of Science ®Google Scholar